Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on News Center UK.
Press releases published on April 11, 2025
Preliminary Results for the Year Ended 31 December 2024
GlobeNewswire
·
April 11, 2025
April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical …
DTFPrinter Launches Custom Transfer Printing Experience for Crafters and Creators
GlobeNewswire
·
April 11, 2025
STOKE ON TRENT, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- DesignBundles.net, the digital marketplace for crafters, graphic designers and businesses, has now launched a new service to help “solve frustrations” in the custom print market. …
Optima Health to acquire Cognate Health Limited
GlobeNewswire
·
April 11, 2025
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) …
ECARX Powers Launch of Geely Galaxy Xingyao 8, Delivering Cutting-Edge Intelligent Cockpit and Driving Experience
GlobeNewswire
·
April 11, 2025
SHANGHAI, April 11, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility tech provider, today announced that its full-stack solution—including the Antora® 1000 computing platform, Skyland® Pro intelligent …
mcl finance and Shawbrook Bank partnership renewed and increased by 50%
GlobeNewswire
·
April 11, 2025
LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- mcl finance has announced the renewal and expansion of its partnership with Shawbrook. Shawbrook Bank, a UK-based specialist lender and savings provider, has renewed its senior debt facility with mcl finance. This …
Vantage Biosciences Doses First Patient in Phase 2 Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy
GlobeNewswire
·
April 11, 2025
LONDON, April 11, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences, a clinical stage biotechnology company advancing innovative therapies for diabetic eye diseases, today announced that the first patient has been successfully dosed in its Phase 2 clinical …